NO20082482L - Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer - Google Patents

Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer

Info

Publication number
NO20082482L
NO20082482L NO20082482A NO20082482A NO20082482L NO 20082482 L NO20082482 L NO 20082482L NO 20082482 A NO20082482 A NO 20082482A NO 20082482 A NO20082482 A NO 20082482A NO 20082482 L NO20082482 L NO 20082482L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
carbonylamino
pyrazoles
pyrrole
well
Prior art date
Application number
NO20082482A
Other languages
English (en)
Norwegian (no)
Inventor
Jayashree Girish Tikhe
Indrawan James Mcalpine
Haitao Li
Anle Yang
Junhu Zhang
Liming Dong
Chuangxing Guo
Yufeng Hong
Mary Catherine Johnson
Susan Elizabeth Kephart
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20082482L publication Critical patent/NO20082482L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20082482A 2005-12-21 2008-06-02 Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer NO20082482L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75334905P 2005-12-21 2005-12-21
US86493206P 2006-11-08 2006-11-08
PCT/IB2006/003646 WO2007072153A2 (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20082482L true NO20082482L (no) 2008-07-02

Family

ID=38189022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082482A NO20082482L (no) 2005-12-21 2008-06-02 Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer

Country Status (26)

Country Link
US (1) US7884117B2 (es)
EP (1) EP1979356B1 (es)
JP (1) JP4635089B2 (es)
KR (1) KR101029167B1 (es)
AP (1) AP2369A (es)
AU (1) AU2006327866B2 (es)
BR (1) BRPI0620354A2 (es)
CA (1) CA2634381C (es)
CR (1) CR10094A (es)
CU (1) CU23751B7 (es)
DK (1) DK1979356T3 (es)
EA (1) EA015513B1 (es)
EC (1) ECSP088558A (es)
ES (1) ES2435405T3 (es)
GE (1) GEP20104974B (es)
HR (1) HRP20130976T1 (es)
IL (1) IL191776A (es)
MA (1) MA30076B1 (es)
ME (1) ME00006B (es)
MY (1) MY151455A (es)
NO (1) NO20082482L (es)
NZ (1) NZ568692A (es)
PL (1) PL1979356T3 (es)
PT (1) PT1979356E (es)
RS (2) RS20080281A (es)
WO (1) WO2007072153A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
DK2620428T3 (da) * 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
BR112013012175A2 (pt) 2010-11-17 2019-09-24 Hoffmann La Roche combinação, coadministração, uso e método
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
HK1200093A1 (en) 2012-03-16 2015-07-31 霍夫曼-拉罗奇有限公司 Methods of treating melanoma with pak1 inhibitors
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10131679B2 (en) 2014-10-31 2018-11-20 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2016281225B2 (en) * 2015-06-15 2020-10-15 Ube Corporation Substituted dihydropyrrolopyrazole derivative
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
JP7530297B2 (ja) 2018-11-14 2024-08-07 Ｕｂｅ株式会社 ジヒドロピロロピラゾール誘導体
CN113164477A (zh) 2018-12-14 2021-07-23 达纳-法伯癌症研究所股份有限公司 C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
EP3902542A4 (en) * 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF
WO2020212484A1 (en) 2019-04-17 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416527C (en) * 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MXPA05000945A (es) 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
GB0229526D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
WO2005030776A1 (en) 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
CA2593428C (en) 2005-01-10 2012-04-17 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors

Also Published As

Publication number Publication date
US7884117B2 (en) 2011-02-08
MA30076B1 (fr) 2008-12-01
EA015513B1 (ru) 2011-08-30
JP4635089B2 (ja) 2011-02-16
MEP0808A (xx) 2010-02-10
AU2006327866B2 (en) 2012-06-14
DK1979356T3 (da) 2013-11-18
PT1979356E (pt) 2013-11-21
EA200801291A1 (ru) 2008-12-30
KR101029167B1 (ko) 2011-04-12
ES2435405T3 (es) 2013-12-19
RS53029B (sr) 2014-04-30
JP2009520805A (ja) 2009-05-28
WO2007072153A8 (en) 2008-08-14
CU20080115A7 (es) 2010-08-30
RS20080281A (sr) 2009-09-08
ME00006B (me) 2010-02-10
US20090318440A1 (en) 2009-12-24
WO2007072153A3 (en) 2007-10-25
IL191776A0 (en) 2008-12-29
EP1979356B1 (en) 2013-09-18
AP2369A (en) 2012-02-29
CA2634381C (en) 2011-03-08
AU2006327866A1 (en) 2007-06-28
KR20080080567A (ko) 2008-09-04
CR10094A (es) 2008-08-01
EP1979356A2 (en) 2008-10-15
HK1128290A1 (en) 2009-10-23
GEP20104974B (en) 2010-04-26
NZ568692A (en) 2011-07-29
MY151455A (en) 2014-05-30
WO2007072153A2 (en) 2007-06-28
BRPI0620354A2 (pt) 2011-11-08
CA2634381A1 (en) 2007-06-28
IL191776A (en) 2013-03-24
HRP20130976T1 (hr) 2013-11-22
ECSP088558A (es) 2008-07-30
CU23751B7 (es) 2012-01-31
AP2008004506A0 (en) 2008-06-30
PL1979356T3 (pl) 2014-01-31

Similar Documents

Publication Publication Date Title
CY1111752T1 (el) Πυρρολοπυραζολες, δυναμικοι αναστολεις κινασης
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
WO2007079164A3 (en) Protein kinase inhibitors
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
DE602005023333D1 (de) Kinaseinhibitoren
ATE433447T1 (de) Pyrimiidinverbindungen
NO20072058L (no) Inhibitorer av interaksjonen mellom MDM2 og P53
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
NO20050828L (no) lndol-3-svovelderivater
NO20065114L (no) Inhibitorer av IAP
WO2006050109A3 (en) Novel kinase inhibitors
NO20071242L (no) Triazolpyridinylsulfanylderivater som P38-MAP-kinaseinhibitorer
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
NO20082256L (no) Pyrazolderivater, preparater som inneholder slike forbindelser, og fremgangsmåter for anvendelse
WO2007000339A8 (en) Bicyclic derivatives as p38 kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application